Open Access
CC BY-NC-ND 4.0 · Thromb Haemost 2022; 122(08): 1369-1378
DOI: 10.1055/s-0042-1749345
New Technologies, Diagnostic Tools and Drugs

Long-Read Sequencing Identifies the First Retrotransposon Insertion and Resolves Structural Variants Causing Antithrombin Deficiency

1   Servicio de Hematología y Oncología Médica, Hospital Universitario Morales Meseguer, Centro Regional de Hemodonación, Instituto Murciano de Investigación Biosanitaria (IMIB-Arrixaca), Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), Universidad de Murcia, Murcia, Spain
,
Jonathan Stephens
2   Department of Haematology, NHS Blood and Transplant Centre, University of Cambridge, Cambridge, United Kingdom
3   NIHR BioResource, Cambridge University Hospitals NHS Foundation Trust, Cambridge Biomedical Campus, Cambridge, United Kingdom
,
1   Servicio de Hematología y Oncología Médica, Hospital Universitario Morales Meseguer, Centro Regional de Hemodonación, Instituto Murciano de Investigación Biosanitaria (IMIB-Arrixaca), Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), Universidad de Murcia, Murcia, Spain
,
Luca Stefanucci
2   Department of Haematology, NHS Blood and Transplant Centre, University of Cambridge, Cambridge, United Kingdom
4   National Health Service Blood and Transplant (NHSBT), Cambridge Biomedical Campus, Cambridge, United Kingdom
5   BHF Centre of Excellence, Division of Cardiovascular Medicine, Addenbrooke's Hospital, Cambridge Biomedical Campus, Cambridge, United Kingdom
,
José Padilla
1   Servicio de Hematología y Oncología Médica, Hospital Universitario Morales Meseguer, Centro Regional de Hemodonación, Instituto Murciano de Investigación Biosanitaria (IMIB-Arrixaca), Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), Universidad de Murcia, Murcia, Spain
,
Antonia Miñano
1   Servicio de Hematología y Oncología Médica, Hospital Universitario Morales Meseguer, Centro Regional de Hemodonación, Instituto Murciano de Investigación Biosanitaria (IMIB-Arrixaca), Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), Universidad de Murcia, Murcia, Spain
,
Nicholas Gleadall
2   Department of Haematology, NHS Blood and Transplant Centre, University of Cambridge, Cambridge, United Kingdom
3   NIHR BioResource, Cambridge University Hospitals NHS Foundation Trust, Cambridge Biomedical Campus, Cambridge, United Kingdom
,
Juan Luis García
6   Servicio de Hematología, Hospital Universitario de Salamanca, Salamanca, Spain
,
María Fernanda López-Fernández
7   Servicio de Hematología, Complexo Hospitalario Universitario de A Coruña, A Coruña, Spain
,
Pierre-Emmanuel Morange
8   Laboratory of Haematology, La Timone Hospital, Marseille, France
9   C2VN, INRAE, INSERM, Aix-Marseille Université, Marseille, France
,
Marja Puurunen
10   The Framingham Heart Study, National Heart, Lung and Blood Institute, Framingham, Massachusetts, United States
,
Anetta Undas
11   Department of Experimental Cardiac Surgery, Anesthesiology and Cardiology, Institute of Cardiology, Jagiellonian University Medical College and John Paul II Hospital, Kraków, Poland
,
12   Banc de Sang i Teixits, Barcelona, Spain
13   Vall d'Hebron Research Institute, Universitat Autònoma de Barcelona (VHIR-UAB), Barcelona, Spain
14   CIBER de Enfermedades Cardiovasculares, Madrid, Spain
,
Frances Lucy Raymond
3   NIHR BioResource, Cambridge University Hospitals NHS Foundation Trust, Cambridge Biomedical Campus, Cambridge, United Kingdom
15   Department of Medical Genetics, University of Cambridge, Cambridge Biomedical Campus, Cambridge, United Kingdom
,
Vicente Vicente
1   Servicio de Hematología y Oncología Médica, Hospital Universitario Morales Meseguer, Centro Regional de Hemodonación, Instituto Murciano de Investigación Biosanitaria (IMIB-Arrixaca), Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), Universidad de Murcia, Murcia, Spain
,
Willem H. Ouwehand
2   Department of Haematology, NHS Blood and Transplant Centre, University of Cambridge, Cambridge, United Kingdom
3   NIHR BioResource, Cambridge University Hospitals NHS Foundation Trust, Cambridge Biomedical Campus, Cambridge, United Kingdom
,
Javier Corral
1   Servicio de Hematología y Oncología Médica, Hospital Universitario Morales Meseguer, Centro Regional de Hemodonación, Instituto Murciano de Investigación Biosanitaria (IMIB-Arrixaca), Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), Universidad de Murcia, Murcia, Spain
,
Alba Sanchis-Juan
2   Department of Haematology, NHS Blood and Transplant Centre, University of Cambridge, Cambridge, United Kingdom
3   NIHR BioResource, Cambridge University Hospitals NHS Foundation Trust, Cambridge Biomedical Campus, Cambridge, United Kingdom
,
NIHR BioResource› Institutsangaben

Funding This work was supported by the National Institute for Health Research England (NIHR) for the NIHR BioResource project (grant numbers RG65966 and RG94028), the PI18/00598, PI21/00174, and PMP21/00052 projects (Instituto de Salud Carlos III, FEDER & Next Generation and the 21642/PDC/21 project (Fundación Séneca).
Preview

Abstract

The identification of inherited antithrombin deficiency (ATD) is critical to prevent potentially life-threatening thrombotic events. Causal variants in SERPINC1 are identified for up to 70% of cases, the majority being single-nucleotide variants and indels. The detection and characterization of structural variants (SVs) in ATD remain challenging due to the high number of repetitive elements in SERPINC1. Here, we performed long-read whole-genome sequencing on 10 familial and 9 singleton cases with type I ATD proven by functional and antigen assays, who were selected from a cohort of 340 patients with this rare disorder because genetic analyses were either negative, ambiguous, or not fully characterized. We developed an analysis workflow to identify disease-associated SVs. This approach resolved, independently of its size or type, all eight SVs detected by multiple ligation-dependent probe amplification, and identified for the first time a complex rearrangement previously misclassified as a deletion. Remarkably, we identified the mechanism explaining ATD in 2 out of 11 cases with previous unknown defect: the insertion of a novel 2.4 kb SINE-VNTR-Alu retroelement, which was characterized by de novo assembly and verified by specific polymerase chain reaction amplification and sequencing in the probands and affected relatives. The nucleotide-level resolution achieved for all SVs allowed breakpoint analysis, which revealed repetitive elements and microhomologies supporting a common replication-based mechanism for all the SVs. Our study underscores the utility of long-read sequencing technology as a complementary method to identify, characterize, and unveil the molecular mechanism of disease-causing SVs involved in ATD, and enlarges the catalogue of genetic disorders caused by retrotransposon insertions.

Author Contributions

B.M.-B., W.H.O., J.C., and A.S.-J. designed the study. M.M.B., L.S., J.P., A.M., N.G., F.L.R., and V.V. helped with the study design. B.M.-B., M.M.B., J.P., and A.M. performed laboratory experiments and analyzed the experimental data. J.S. performed sample preparation and executed long-read sequencing. A.S.-J. developed the analysis workflow for long-read sequencing, applied this to data processing, and performed the computational and statistical analyses. B.M.-B. performed computational analyses and variant validation. J.J.L.C. and F.V. provided valuable insight into microarray and NGS data analysis. A.U., M.F., M.P., and P.M. recruited participants and collected the clinical data and samples. B.M.-B., W.H.O., J.C., and A.S.-J. wrote the manuscript. All authors read and approved the final version of the manuscript.


Data and Code Availability

The workflow developed for the detection of structural variants is publicly available at http://github.com/who-blackbird/magpie.


Patient Consent

All included subjects gave their written informed consent to enter the study.


Ethical Approval

This study was approved by the Ethics Committee of Morales Meseguer Hospital and the East of England Cambridge South National Institutional Review Board (13/EE/0325). The research conforms to the principles of the Declaration of Helsinki and their later amendments.


Supplementary Material



Publikationsverlauf

Eingereicht: 16. September 2021

Angenommen: 10. Januar 2022

Artikel online veröffentlicht:
28. Juni 2022

© 2022. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/)

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany